Given the prognostic value of early molecular response (EMR) and the ultimate objective of TFR, there is a growing need to elucidate how early BCR::ABL1 kinetics influence long-term molecular outcomes in pediatric CML. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.